Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
